Synapse - Works

Results (904)

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial

Journal Article

Tolaney, S. M.; Tarantino, P.; Graham, N.; Tayob, N.; Parè, L.; Villacampa, G.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer

Journal Article

Shepherd, J. H.; Ballman, K.; Polley, M. Y. C.; Campbell, J. D.; Fan, C.; Selitsky, S.; Fernandez-Martinez, A.; Parker, J. S.; Hoadley, K. A.; Hu, Z.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention

Review

Delahanty, L. M.; Wadden, T. A.; Goodwin, P. J.; Alfano, C. M.; Thomson, C. A.; Irwin, M. L.; Neuhouser, M. L.; Crane, T. E.; Frank, E.; Spears, P. A.; more...
Obesity (2022)

Fulltext@MSK | Save

Physical activity, weight, and outcomes in patients receiving chemotherapy for metastatic breast cancer (C40502/Alliance)

Journal Article

Ligibel, J. A.; Huebner, L.; Rugo, H. S.; Burstein, H. J.; Toppmeyer, D. L.; Anders, C. K.; Ma, C.; Barry, W. T.; Suman, V.; Carey, L. A.; more...
JNCI Cancer Spectrum (2021)

Fulltext@MSK | Save

Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy

Journal Article

Magbanua, M. J. M.; Hendrix, L. H.; Hyslop, T.; Barry, W. T.; Winer, E. P.; Hudis, C.; Toppmeyer, D.; Carey, L. A.; Partridge, A. H.; Pierga, J. Y.; more...
JNCI: Journal of the National Cancer Institute (2021)

Fulltext@MSK | Save

Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Meeting Abstract

Ma, C. X.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)

Meeting Abstract

Ellis, M. J.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Journal Article

Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
Nature Cancer (2020)

Fulltext@MSK | Save

Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer

Journal Article

Fernandez-Martinez, A.; Krop, I. E.; Hillman, D. W.; Polley, M. Y.; Parker, J. S.; Huebner, L.; Hoadley, K. A.; Shepherd, J.; Tolaney, S.; Lynn Henry, N.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or Ill estrogen receptor-positive HER2-negative breast cancer (ER+HER2-BC) in postmenopausal (PM) women: Alliance A011106

Meeting Abstract

Ma, C. X.; Suman, V. J.; Leitch, A. M.; Sanati, S.; Vij, K. R.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O. M.; Guenther, J. M.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save